Cargando…
A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod
BACKGROUND: Fingolimod is the first oral disease-modifying therapy indicated for the treatment of patients with relapsing forms of multiple sclerosis (MS) to reduce the frequency of clinical relapses and delay the progression of physical disability caused by MS. OBJECTIVE: To obtain data from MS pat...
Autores principales: | Hanson, Kristin A, Agashivala, Neetu, Stringer, Sonja M, Balantac, Zaneta, Brandes, David W |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3633540/ https://www.ncbi.nlm.nih.gov/pubmed/23620662 http://dx.doi.org/10.2147/PPA.S41992 |
Ejemplares similares
-
Treatment selection and experience in multiple sclerosis: survey of neurologists
por: Hanson, Kristin A, et al.
Publicado: (2014) -
Compliance to fingolimod and other disease modifying treatments in multiple sclerosis patients, a retrospective cohort study
por: Agashivala, Neetu, et al.
Publicado: (2013) -
Treatment satisfaction and quality of life in patients treated with fingolimod
por: Mékiès, Claude, et al.
Publicado: (2018) -
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
por: Bergvall, Niklas, et al.
Publicado: (2014) -
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial
por: Calkwood, Jonathan, et al.
Publicado: (2014)